logo oncology-news

Онкология  >  Новости онкологии

При финансовой поддержке logo MSD Oncology

Cholangiocarcinoma: nab-paclitaxel/gemcitabine offers alternative

Phase 2 trial shows efficacy but misses PFS endpoint.